Reviews/Anti CGRP Antibodies/Medication overuse headache remission with CGRP antibodies
Medication Overuse · CGRP-MOH-02 · v2
Medication overuse headache happens when frequent use of acute headache drugs makes headaches worse. This evidence looks at whether anti-CGRP antibodies, a newer class of preventive migraine drugs, help patients stop overusing and return below the overuse threshold. One carefully designed trial [19] found that patients on the higher antibody dose reached remission more often than those on placebo, and a second trial [22] and several real-world clinics [2][3][25] reported many patients no longer overusing after treatment. The panel judged the claim well supported because the effect shows up across different drugs, countries and study types. It stopped short of the top tier because a large share of placebo patients also remitted, the lower dose did not clearly beat placebo, remission is defined by counting medication days rather than proving a lasting cure, and much of the supporting data has no comparison group.
A pre-registered Phase 4 randomised trial [19] met MOH remission as its primary endpoint, with 69.1% remission on erenumab 140 mg versus 52.6% on placebo (OR 2.01, P<.001). A second Class I trial [22] showed eptinezumab superior to placebo on migraine days in chronic migraine with MOH. Three independent real-world cohorts report that patients no longer met the medication-overuse definition after treatment: 67.7% [2], 60.6% [3], and 46.9% [25]. Prolonged treatment over three years was associated with lower relapse to medication overuse (1.3% at D3 vs 34.2% at D1) [33]. The findings align in direction across multiple agents, centres and designs. The contested point: The division is over how much of the remission is attributable to the antibody. In [19] 52.6% of placebo patients also remitted, the 140 mg increment is roughly 16.5 points, and the 70 mg dose did not separate from placebo (60.3% vs 52.6%, P=.13); the real-world rates [2][3][25] lack any comparator.
All 36 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
In the only pivotal RCT [19], 52.6% of placebo patients achieved MOH remission, so a majority remit without active antibody; the effective-dose increment is only ~16.5 points and the 70 mg dose did not separate from placebo (60.3% vs 52.6%, p=0.13). The claim is true but the drug-specific effect is modest and dose-dependent.
The headline real-world resolution rates ([2] 67.7%, [3] 60.6%, [25] 46.9%) come from uncontrolled cohorts; regression to the mean, natural history and concurrent advice to cut acute medication cannot be separated from the antibody effect.
Where it remains uncertain. A majority of placebo patients also remitted and the 70 mg dose did not separate from placebo (P=.13) [19], while the supporting real-world rates are uncontrolled [2][3][25].
Aleatory
A majority of placebo patients remitted in [19] (52.6%), reflecting natural fluctuation and regression to the mean that varies between patients.
Epistemic
[19] enrolled only the nonopioid cohort, so remission in opioid-overuse MOH, where relapse is typically high, is untested in this corpus.
The load-bearing papers from a corpus of 36, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Real-world cohort: 67.7% achieved MO remission on fremanezumab.
“Remission from CM to episodic migraine and from MO to no-MO occurred in 75% and 67.7% of the patients.”
Panel auditInternal validity: low · scope of inference: High-frequency episodic and chronic migraine patients with medication overuse treated with fremanezumab in routine Italian practice.Key limitations: uncontrolled · small sample · no comparator for remission
Real-world cohort: 60.6% of CM-MO patients remitted from overuse.
“60.6% (60/99) no longer satisfied MO definition.”
Panel auditInternal validity: medium · scope of inference: Chronic migraine patients with medication overuse on erenumab or galcanezumab in real-life practice.Key limitations: no control arm · observational
Pivotal controlled evidence: MOH remission as primary endpoint, significant for 140 mg over placebo.
“monthly, 140 mg, erenumab injections safely and effectively achieved MOH remission in patients with nonopioid CM-MOH within 6 months.”
Panel auditInternal validity: high · scope of inference: Adults with chronic migraine and nonopioid medication overuse with prior preventive failure.Key limitations: high placebo remission rate (52.6%) · 70 mg not significant vs placebo · nonopioid only
3 of 36 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Controlled Class I evidence plus consistent independent real-world data support that antibodies achieve MOH remission, but a modest placebo-adjusted increment and surrogate endpoint keep confidence in the Likely band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Opioid-overuse MOH. The pivotal RCT [19] excluded opioid overusers, so the claim does not cover the subgroup with the highest relapse risk. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial of an anti-CGRP antibody in opioid-overuse MOH with MOH remission as the primary endpoint.
Open question: Do anti-CGRP antibodies achieve MOH remission over placebo in opioid-overuse MOH? Why it is still open: The only pivotal RCT [19] enrolled only the nonopioid cohort, leaving opioid MOH uncovered.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19